Celebrex (celecoxib) is the first drug to be approved for a hereditary form of colorectal cancer

Celebrex (celecoxib) is the first drug to be approved for a hereditary form of colorectal cancer.

It'll be used to help reduce the number of intestinal polyps in patients with familial adenomatous polyposis (FAP).

Blocking the COX-2 enzyme seems to reduce blood supply to the polyp and therefore inhibit growth.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote